Madison, WI – September 17, 2024 – Invenra Inc. is pleased to announce the addition of three distinguished professionals to its Board of Directors: Saira Ramasastry, Heather Preston, MD, and... read more →
Madison, WI – Aug 23, 2024 – Invenra Inc. is pleased to announce that its innovative bispecific antibody, INV724, developed for the treatment of neuroblastoma, has been awarded both Rare... read more →
MADISON, Wisc.--(BUSINESS WIRE)--Invenra’s collaboration partner, Exelixis, Inc. (NASDAQ: EXEL) has announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XB010 in patients with locally... read more →
Madison, WI – April 9, 2024 – Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical... read more →
MADISON, Wis. – Apr 2, 2024 – Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and... read more →
- Expanded collaboration to include an additional 20 targets for multi-specific antibody, antibody-drug conjugate, and other biologic candidate discovery and development - ALAMEDA, Calif., & MADISON, Wis. – August 16,... read more →